An alternative might be to use lipase inhibitors and combinations of clinically relevant lipoxygenase and cyclooxygenase inhibitors to block ligand generation and prevent the activation of PPARδ.48, 49 On the basis of the apparent importance of PPARδ in mediating the behavior of aggressive breast cancer cells, it would appear that strategies to target this nuclear receptor may ultimately improve the outcomes of breast cancer patients. Here, PPARD is linked to breast carcinoma.